🇺🇸 FDA
Pipeline program

aerosol inhaled amikacin

B2017-197R

Phase 1 small_molecule completed

Quick answer

aerosol inhaled amikacin for Chronic Obstructive Pulmonary Disease (COPD) is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Chronic Obstructive Pulmonary Disease (COPD)
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials